AIMS/HYPOTHESIS: Exercise training improves glucose homeostasis, but large inter-individual differences are reported, suggesting a role of genetic factors. We investigated whether variants either confirmed or newly identified as diabetes susceptibility variants through genome-wide association studies (GWAS) modulate changes in phenotypes derived from an IVGTT in response to an endurance training programme. METHODS: We analysed eight polymorphisms in seven type 2 diabetes genes (CDKAL1 rs7756992; CDKN2A and CDKN2B rs10811661 and rs564398; HHEX rs7923837; IGF2BP2 rs4402960; KCNJ11 rs5215; PPARG rs1801282; and TCF7L2 rs7903146) in a maximum of 481 sedentary, non-diabetic white individuals, who participated in a 20-week endurance training programme. Associations were tested between the variants and changes in IVGTT-derived phenotypes. RESULTS: The only evidence of association with training response was found with PPARG rs1801282 (Pro12Ala). We observed that Ala carriers experienced greater increase in overall glucose tolerance (Deltaglucose disappearance index Ala/Ala 0.22 +/- 0.22, Pro/Ala 0.14 +/- 0.06, Pro/Pro 0.004 +/- 0.03; p = 0.0008), glucose effectiveness (Ala/Ala 0.28 +/- 0.41, Pro/Ala 0.44 +/- 0.14, Pro/Pro 0.09 +/- 0.06; p = 0.004), acute insulin response to glucose (Ala/Ala 64.21 +/- 37.73, Pro/Ala -11.92 +/- 40.30, Pro/Pro -46.30 +/- 14.70; p = 0.03) and disposition index (Ala/Ala 551.8 +/- 448.5, Pro/Ala 534.6 +/- 218.3, Pro/Pro -7.44 +/- 88.18; p = 0.003). CONCLUSIONS/ INTERPRETATION: Compared with Pro/Pro individuals, PPARG Ala carriers experienced greater improvements in glucose and insulin metabolism in response to regular endurance training. However, we did not find evidence of association between type 2 diabetes susceptibility variants recently identified through GWAS and glucose homeostasis response to exercise. Our results extend those of previous studies showing that Ala carriers appear to be more responsive to beneficial health effects of lifestyle interventions.
AIMS/HYPOTHESIS: Exercise training improves glucose homeostasis, but large inter-individual differences are reported, suggesting a role of genetic factors. We investigated whether variants either confirmed or newly identified as diabetes susceptibility variants through genome-wide association studies (GWAS) modulate changes in phenotypes derived from an IVGTT in response to an endurance training programme. METHODS: We analysed eight polymorphisms in seven type 2 diabetes genes (CDKAL1rs7756992; CDKN2A and CDKN2Brs10811661 and rs564398; HHEXrs7923837; IGF2BP2rs4402960; KCNJ11rs5215; PPARG rs1801282; and TCF7L2rs7903146) in a maximum of 481 sedentary, non-diabetic white individuals, who participated in a 20-week endurance training programme. Associations were tested between the variants and changes in IVGTT-derived phenotypes. RESULTS: The only evidence of association with training response was found with PPARG rs1801282 (Pro12Ala). We observed that Ala carriers experienced greater increase in overall glucose tolerance (Deltaglucose disappearance index Ala/Ala 0.22 +/- 0.22, Pro/Ala 0.14 +/- 0.06, Pro/Pro 0.004 +/- 0.03; p = 0.0008), glucose effectiveness (Ala/Ala 0.28 +/- 0.41, Pro/Ala 0.44 +/- 0.14, Pro/Pro 0.09 +/- 0.06; p = 0.004), acute insulin response to glucose (Ala/Ala 64.21 +/- 37.73, Pro/Ala -11.92 +/- 40.30, Pro/Pro -46.30 +/- 14.70; p = 0.03) and disposition index (Ala/Ala 551.8 +/- 448.5, Pro/Ala 534.6 +/- 218.3, Pro/Pro -7.44 +/- 88.18; p = 0.003). CONCLUSIONS/ INTERPRETATION: Compared with Pro/Pro individuals, PPARGAla carriers experienced greater improvements in glucose and insulin metabolism in response to regular endurance training. However, we did not find evidence of association between type 2 diabetes susceptibility variants recently identified through GWAS and glucose homeostasis response to exercise. Our results extend those of previous studies showing that Ala carriers appear to be more responsive to beneficial health effects of lifestyle interventions.
Entities:
Keywords:
Diabetes susceptibility genes; IVGTT-derived phenotypes; Polymorphisms; Response to exercise
Authors: Normand G Boulé; S John Weisnagel; Timo A Lakka; Angelo Tremblay; Richard N Bergman; Tuomo Rankinen; Arthur S Leon; James S Skinner; Jack H Wilmore; D C Rao; Claude Bouchard Journal: Diabetes Care Date: 2005-01 Impact factor: 19.112
Authors: C Thamer; M Haap; A Volk; E Maerker; R Becker; O Bachmann; F Machicao; H U Häring; M Stumvoll Journal: Horm Metab Res Date: 2002-03 Impact factor: 2.936
Authors: Virpi I Lindi; Matti I J Uusitupa; Jaana Lindström; Anne Louheranta; Johan G Eriksson; Timo T Valle; Helena Hämäläinen; Pirjo Ilanne-Parikka; Sirkka Keinänen-Kiukaanniemi; Markku Laakso; Jaakko Tuomilehto Journal: Diabetes Date: 2002-08 Impact factor: 9.461
Authors: Timo A Lakka; Tuomo Rankinen; S John Weisnagel; Yvon C Chagnon; Treva Rice; Arthur S Leon; James S Skinner; Jack H Wilmore; D C Rao; Claude Bouchard Journal: Diabetes Date: 2003-06 Impact factor: 9.461
Authors: Ray C Boston; Darko Stefanovski; Peter J Moate; Anne E Sumner; Richard M Watanabe; Richard N Bergman Journal: Diabetes Technol Ther Date: 2003 Impact factor: 6.118
Authors: James M Hagberg; Tuomo Rankinen; Ruth J F Loos; Louis Pérusse; Stephen M Roth; Bernd Wolfarth; Claude Bouchard Journal: Med Sci Sports Exerc Date: 2011-05 Impact factor: 5.411
Authors: Armando Peña; Daniel McNeish; Stephanie L Ayers; Micah L Olson; Kiley B Vander Wyst; Allison N Williams; Gabriel Q Shaibi Journal: Pediatr Diabetes Date: 2020-10-08 Impact factor: 4.866
Authors: Thomas P J Solomon; Steven K Malin; Kristian Karstoft; Sangeeta R Kashyap; Jacob M Haus; John P Kirwan Journal: J Clin Endocrinol Metab Date: 2013-08-21 Impact factor: 5.958
Authors: Thomas P J Solomon; Steven K Malin; Kristian Karstoft; Jacob M Haus; John P Kirwan Journal: JAMA Intern Med Date: 2013-10-28 Impact factor: 21.873